Skip to main content
. 2020 Jun 25;123(6):1024–1032. doi: 10.1038/s41416-020-0951-2

Fig. 4. ERG exon 4 SSOs have anti-tumour effects in vivo.

Fig. 4

a Subcutaneous tumour growth of the ERG + MG63 cell line was measured twice weekly following IP injection of E43′ SSOs. Tumour measurements and dosing were performed on the same day. b Representative images of subcutaneous tumours (indicated by highlighted regions) in situ. c Measurements of body weight following systemic administration of SSOs. d Endpoint tumour weights from mice treated with SSOs (n = 8 for untreated; n = 11 for scrambled ctrl SSO; n = 10 for E43′ SSO). e Representative RT-PCR panels (left) and quantifications (right) of exon 4 skipping (arrow) from tumour tissue extracted at endpoints (n = 5 for untreated; n = 7 for scrambled ctrl and E43′ SSOs). f Representative panels for ERG and GAPDH (loading control) western blotting (left) in tumour tissue extracted from mice at endpoints. Quantification of ERG western blotting in tumours shown on right (n = 3 for untreated; n = 7 for scrambled ctrl SSO; n = 8 for E43′ SSO). ERG protein expression levels were normalised to GAPDH. *** = p < 0.001, ** = p < 0.01, * = p < 0.05. Scr ctrl SSO Scrambled control SSO.